The introduction of copay accumulator programs has significantly increased the out-of-pocket (OOP) costs for patients, posing an existential threat to certain prescription specialty treatments.
Specialty pharma manufacturers are taking rapid steps to ensure both patient access to medicine and ongoing adherence by developing a comprehensive copay accumulator mitigation strategy that meets the full scope of the threat.
Best Practices, LLC undertook benchmarking research to determine the impact of payer-imposed copay accumulator programs on specialty pharma manufacturers and their patients. This research examines the most effective tactics and strategies employed by organizations for mitigating the impact of copay accumulator programs.
This report will provide market access and reimbursement leaders with critical benchmarks and insights around: copay accumulator threat assessment, leading and lagging indicators of copay accumulator impact, decision triggers to counteract copay accumulators, effective copay accumulator mitigation strategies and tactics, use of new forms of copayment, types of non-coupon copayment approaches, financial assistance outlays, and key performance indicators to measure the effectiveness of copay accumulator mitigation strategies.
This report also highlights the operational hurdles, success factors and lessons learned in implementing an effective copay accumulator mitigation strategy.